DSG2 and neoplasm: To assess the role of expression of the DSG2 and CD46 receptors on ONCOS‐102 treatment of patients with solid tumors from a previously reported phase I trial,28 we retrospectively investigated DSG2 and CD46 RNA expression levels in patient tumor samples and their relationship with viral load in blood, and with the number of tumor‐infiltrating leukocytes (TILs).